Joe Y Chang

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 117:4707-13. 2011
  2. ncbi Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 7:152. 2012
  3. ncbi High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy
    Joe Y Chang
    Department of Radiation Oncology, Epidemiology, and Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:2894-8. 2005
  4. ncbi Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 80:1350-7. 2011
  5. ncbi Esophageal cancer: diagnosis and management
    Steven H Lin
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, Texas 77030, USA
    Chin J Cancer 29:843-54. 2010
  6. ncbi Image-guided radiation therapy for non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 3:177-86. 2008
  7. ncbi Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1087-96. 2006
  8. ncbi Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 64:1482-94. 2006
  9. ncbi Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:967-71. 2008
  10. ncbi Surgical patterns of care in operable lung carcinoma treated with radiation
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:526-31. 2006

Detail Information

Publications75

  1. ncbi Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
    Cancer 117:4707-13. 2011
    ..They report early results of a phase 2 study of high-dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival...
  2. ncbi Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Radiat Oncol 7:152. 2012
    ..However, factors that may predict toxicity or survival are largely unknown. We sought here to identify predictors of survival and pneumonitis after SABR for NSCLC in a relatively large single-institution series...
  3. ncbi High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy
    Joe Y Chang
    Department of Radiation Oncology, Epidemiology, and Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:2894-8. 2005
    ....
  4. ncbi Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 80:1350-7. 2011
    ..To analyze the toxicity and patterns of failure of proton therapy given in ablative doses for medically inoperable early-stage non-small cell lung cancer (NSCLC)...
  5. ncbi Esophageal cancer: diagnosis and management
    Steven H Lin
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 97, Houston, Texas 77030, USA
    Chin J Cancer 29:843-54. 2010
    ..This article reviews some of these controversies, including the role for surgery in patients treated with definitive chemoradiation. At the end, we will also outline recommendations regarding radiotherapy procedures and techniques...
  6. ncbi Image-guided radiation therapy for non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 3:177-86. 2008
    ....
  7. ncbi Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:1087-96. 2006
    ..To compare dose-volume histograms (DVH) in patients with non-small-cell lung cancer (NSCLC) treated by photon or proton radiotherapy...
  8. ncbi Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 64:1482-94. 2006
    ..To overcome radiation resistance in esophageal adenocarcinoma by tumor-specific apoptotic gene targeting using tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)...
  9. ncbi Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:967-71. 2008
    ..To evaluate the efficacy and adverse effects of image-guided stereotactic body radiation therapy (SBRT) in centrally/superiorly located non-small-cell lung cancer (NSCLC)...
  10. ncbi Surgical patterns of care in operable lung carcinoma treated with radiation
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 1:526-31. 2006
    ..To determine the national surgical practice patterns of care for operable lung cancer patients treated with radiation...
  11. ncbi The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy
    Arya Amini
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 94:914-20. 2012
    ..We assessed the role of consolidative therapies (postoperative radiation therapy and chemotherapy) for such patients...
  12. ncbi Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung canc
    Xiaodong Zhang
    Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 77:357-66. 2010
    ....
  13. ncbi Evaluation of tumor position and PTV margins using image guidance and respiratory gating
    Christopher Nelson
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:1578-85. 2010
    ..To evaluate the margins currently used to generate the planning target volume for lung tumors and to determine whether image-guided patient setup or respiratory gating is more effective in reducing uncertainties in tumor position...
  14. ncbi 4D Proton treatment planning strategy for mobile lung tumors
    Yixiu Kang
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Radiat Oncol Biol Phys 67:906-14. 2007
    ..To investigate strategies for designing compensator-based 3D proton treatment plans for mobile lung tumors using four-dimensional computed tomography (4DCT) images...
  15. ncbi Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer
    Samir Sejpal
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:3004-13. 2011
    ..We hypothesized that proton beam therapy for most patients with NSCLC could permit higher tumor doses with less normal-tissue toxicity than photon RT delivered as 3-dimensional conformal RT (3D-CRT) or intensity-modulated RT (IMRT)...
  16. ncbi Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy
    Ritsuko Komaki
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
    Semin Oncol 32:S92-8. 2005
    ..AMF reduced the incidence of grade 3/4 lung fibrosis among higher MS. These data suggest that MS might help identify subgroups of patients who could receive more benefit from AMF with respect to lung damage...
  17. ncbi Adaptive/nonadaptive proton radiation planning and outcomes in a phase II trial for locally advanced non-small cell lung cancer
    Eugene J Koay
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:1093-100. 2012
    ..To analyze dosimetric variables and outcomes after adaptive replanning of radiation therapy during concurrent high-dose protons and chemotherapy for locally advanced non-small cell lung cancer (NSCLC)...
  18. ncbi Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer
    Hasan Murshed
    Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:1258-67. 2004
    ..The dosimetric benefits of IMRT for advanced-stage non-small-cell lung cancer must be evaluated further in clinical trials...
  19. ncbi Radiotherapy sensitization by tumor-specific TRAIL gene targeting improves survival of mice bearing human non-small cell lung cancer
    Xiaochun Zhang
    Department of Experimental Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:6657-68. 2005
    ..Ad/TRAIL-F/RGD may improve the therapeutic ratio of radiotherapy in NSCLC...
  20. ncbi Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer
    Steven P Register
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 80:1015-22. 2011
    ....
  21. ncbi Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation
    Ann Hoge Klopp
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:1409-16. 2007
    ..We investigated patterns of treatment failure in patients treated to a PET-defined radiotherapy target and evaluated the effect of standardized uptake value (SUV) on recurrence after radiotherapy...
  22. ncbi A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer
    Zhongxing Liao
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 11:3342-8. 2005
    ....
  23. ncbi Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer
    Isis W Gayed
    Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Thorac Oncol 4:179-84. 2009
    ..We evaluated the prevalence of myocardial perfusion defects using myocardial perfusion imaging (MPI) after chemoradiation or radiation therapy (CRT/RT) in lung cancer patients and described their patterns in relation to tumor location...
  24. ncbi Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:779-85. 2007
    ..To retrospectively compare outcomes for patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) treated at our institution with concurrent chemoradiation with or without induction chemotherapy...
  25. ncbi Consequences of anatomic changes and respiratory motion on radiation dose distributions in conformal radiotherapy for locally advanced non-small-cell lung cancer
    Keith R Britton
    Department of Radiation Physics, Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 73:94-102. 2009
    ..To determine the effect of interfractional changes in anatomy on the target and normal tissue dose distributions during course of radiotherapy in non-small-cell lung cancer patients...
  26. ncbi Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly
    Shervin M Shirvani
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:1060-70. 2012
    ....
  27. ncbi Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer
    Michelle A T Hildebrandt
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e12402. 2010
    ..These results suggest that genetic variations among inflammation pathway genes may modulate the development of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events...
  28. ncbi Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation
    Patrick Kelly
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 78:1387-93. 2010
    ..In this study, we retrospectively reviewed outcomes after SBRT for recurrent disease among patients previously given radiation therapy to the chest...
  29. ncbi Assessment of gross tumor volume regression and motion changes during radiotherapy for non-small-cell lung cancer as measured by four-dimensional computed tomography
    Keith R Britton
    Division of Radiation Oncology, Department of Radiation Physics, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1036-46. 2007
    ..To investigate the magnitudes of the changes in mobility and volume of locally advanced non-small-cell lung cancer (NSCLC) tumors during radiotherapy, using four-dimensional computed tomography (4DCT)...
  30. ncbi Effects of interfractional motion and anatomic changes on proton therapy dose distribution in lung cancer
    Zhouguang Hui
    Department of Radiation Phyiscs, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 72:1385-95. 2008
    ..Proton doses are sensitive to intra- and interfractional anatomic changes. We analyzed the effects of interfractional anatomic changes in doses to lung tumors treated with proton therapy...
  31. ncbi Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy
    Hui Liu
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 84:1017-23. 2012
    ..To determine the incidence of and risk factors for radiation pneumonitis (RP) after stereotactic ablative radiation therapy (SABR) to the lung in patients who had previously undergone conventional thoracic radiation therapy...
  32. ncbi Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy
    James Welsh
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 81:91-6. 2011
    ..We attempted here to identify dose-volume parameters that predict chest wall toxicity (pain and skin reactions) in patients receiving thoracic SBRT...
  33. ncbi Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer
    Shervin M Shirvani
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 82:e91-7. 2012
    ....
  34. ncbi Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?
    Susan L McGovern
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 115:3233-42. 2009
    ..To the authors' knowledge, sex-based differences in outcomes among the population of nonsmall cell lung cancer (NSCLC) patients receiving radiation have not been well defined...
  35. ncbi Daily alignment results of in-room computed tomography-guided stereotactic body radiation therapy for lung cancer
    Hitoshi Ikushima
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 79:473-80. 2011
    ....
  36. ncbi Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer
    Anurag Chandra
    Department of Radiation Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, USA
    Radiother Oncol 77:247-53. 2005
    ..CONCLUSIONS: Dose-volume of exposed normal lung can be reduced with IMRT, though clinical investigations are warranted to assess IMRT treatment outcome of esophagus cancers...
  37. ncbi Cine computed tomography without respiratory surrogate in planning stereotactic radiotherapy for non-small-cell lung cancer
    Adam C Riegel
    Department of Imaging Physics, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 73:433-41. 2009
    ....
  38. ncbi Assessment of lung tumor motion and setup uncertainties using implanted fiducials
    Christopher Nelson
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 67:915-23. 2007
    ..The purpose of this work was to assess the magnitude of setup uncertainties and respiratory-induced motion of lung tumors by monitoring the location of fiducials implanted in the vicinity of the tumors...
  39. ncbi Preserving functional lung using perfusion imaging and intensity-modulated radiation therapy for advanced-stage non-small cell lung cancer
    Yoshiyuki Shioyama
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 68:1349-58. 2007
    ..To assess quantitatively the impact of incorporating functional lung imaging into intensity-modulated radiation therapy planning for locally advanced non-small cell lung cancer (NSCLC)...
  40. ncbi Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma
    David C Rice
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 69:350-7. 2007
    ..To determine the incidence of fatal pulmonary events after extrapleural pneumonectomy and hemithoracic intensity-modulated radiotherapy (IMRT) for malignant pleural mesothelioma...
  41. ncbi FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy
    Zuo Lin Xiang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Radiat Oncol 7:144. 2012
    ..We studied whether maximum standardized uptake values (SUV) from [18 F] PET/CT predict clinical outcome after concurrent proton/chemotherapy for stage III non-small cell lung cancer (NSCLC)...
  42. ncbi Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy?
    Enzhuo M Quan
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 84:e69-76. 2012
    ....
  43. ncbi Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer
    Ritsuko Komaki
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center Houston, TX, USA
    Front Oncol 1:52. 2011
    ..Conclusion: Although preliminary, our results suggest that adding celecoxib to concurrent chemoradiation for inoperable NSCLC is safe and can improve outcome without increasing normal tissue toxicity...
  44. ncbi Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography
    Muthuveni Ezhil
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, Houston, USA
    Radiat Oncol 4:4. 2009
    ..To determine the optimal approach to delineating patient-specific internal gross target volumes (IGTV) from four-dimensional (4-D) computed tomography (CT) image data sets used in the planning of radiation treatment for lung cancers...
  45. ncbi Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy
    Xifeng Wu
    Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77030, USA
    J Natl Cancer Inst 103:817-25. 2011
    ..Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC)...
  46. ncbi A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials
    Christopher Nelson
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Appl Clin Med Phys 9:2766. 2008
    ..Software that matches fiducial markers on 2D and 3D images is effective for aligning both static and moving fiducials before treatment and can be implemented to reduce patient setup uncertainties...
  47. ncbi Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer
    James W Welsh
    Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 31:895-902. 2013
    ..Additional end points were radiologic response and safety...
  48. ncbi Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer
    Xu Zhang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 83:1558-65. 2012
    ..We analyzed whether positron emission tomography (PET)/computed tomography standardized uptake values (SUVs) after stereotactic body radiotherapy (SBRT) could predict local recurrence (LR) in non-small-cell lung cancer (NSCLC)...
  49. ncbi Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer
    Erik P Sulman
    Department of Radiation Oncology, The University of Texas M, d, Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA
    Radiat Oncol 4:5. 2009
    ....
  50. ncbi Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status
    Min P Kim
    Department of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Thorac Surg 90:884-90; discussion 890-1. 2010
    ..We hypothesized that these patients would have similar survival to patients with incomplete response to therapy...
  51. ncbi Implementation of feedback-guided voluntary breath-hold gating for cone beam CT-based stereotactic body radiotherapy
    Yong Peng
    Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 80:909-17. 2011
    ..To analyze tumor position reproducibility of feedback-guided voluntary deep inspiration breath-hold (FGBH) gating for cone beam computed tomography (CBCT)-based stereotactic body radiotherapy (SBRT)...
  52. ncbi Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus
    Xiaochun Zhang
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:2813-23. 2008
    ..Because CSCs require telomerase to proliferate, a telomerase-specific oncolytic adenoviral vector carrying apoptotic tumor necrosis factor-related apoptosis-inducing ligand and E1A gene (Ad/TRAIL-E1) may preferentially target CSCs...
  53. ncbi Stereotactic body radiation therapy for stage I non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 0097, USA
    Thorac Surg Clin 17:251-9. 2007
    ..a reliable immobilization device and consideration of image-guided tumor motion are crucial. The optimal dose regimen remains unclear, but a BED greater than 100 Gy seems warranted...
  54. ncbi Targeted functional imaging of estrogen receptors with 99mTc-GAP-EDL
    Nobukazu Takahashi
    Division of Diagnostic Imaging, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Eur J Nucl Med Mol Imaging 34:354-62. 2007
    ..To evaluate the feasibility of using (99m)Tc-glutamate peptide-estradiol in functional imaging of estrogen receptor-positive [ER(+)] diseases...
  55. ncbi Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection
    Noah A Taylor
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 58:204-12. 2004
    ..To improve survival, however, newer systemic agents that reduce and control distant metastasis are required...
  56. ncbi Improving radiation conformality in the treatment of non-small cell lung cancer
    Joe Y Chang
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Semin Radiat Oncol 20:171-7. 2010
    ....
  57. ncbi Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma
    Charles Lu
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 106:441-7. 2006
    ....
  58. ncbi The potential for dose escalation in lung cancer as a result of systematically reducing margins used to generate planning target volume
    Christopher Nelson
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 65:573-86. 2006
    ..To determine how much the radiation dose to lung tumors could be increased as the margins used to generate planning target volume (PTV) are reduced...
  59. ncbi Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer
    Joe Y Chang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 7:255-9. 2005
    ..We are conducting preclinical and clinical studies for imaging-guided proton radiotherapy in NSCLC. In this paper, we discuss the preliminary data, IMRT treatment guidelines, and ongoing studies for proton therapy in NSCLC...
  60. ncbi Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac
    Oleg N Vassiliev
    Department of Radiation Physics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Appl Clin Med Phys 10:2880. 2009
    ..The study concludes that radiotherapy with unflattened beams is feasible and requires substantially less beam-on time, facilitating breath-hold and gating techniques...
  61. ncbi The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer
    Isis W Gayed
    Department of Nuclear Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    J Nucl Med 47:1756-62. 2006
    ..However, the prevalence and association of such abnormalities with RT in esophageal cancer patients have not been investigated previously...
  62. ncbi Effect of combining anti-epidermal growth factor receptor antibody C225 and radiation on DU145 prostate cancer
    Matthew Wagener
    Department of Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 19:1071-7. 2008
    ..We drew the conclusion that the inhibition of EGFR augments the radiation killing of DU145 prostate cancer via a combination of cytostatic, necrotic and apoptotic mechanisms...
  63. ncbi Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms
    Xin Shelley Wang
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:4485-91. 2006
    ....
  64. ncbi Proton therapy in clinical practice
    Hui Liu
    Sun Yat sen University Cancer Center, Guangzhou, Guangdong 510060, P R China
    Chin J Cancer 30:315-26. 2011
    ..In this article, we review practical issues of proton therapy, describe its image-guided treatment planning and delivery, discuss clinical outcome for cancer patients, and suggest challenges and the future development of proton therapy...
  65. ncbi Validation of an accelerated 'demons' algorithm for deformable image registration in radiation therapy
    He Wang
    Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Phys Med Biol 50:2887-905. 2005
    ..Together, these results suggest that the accelerated demons algorithm has significant potential for delineating and tracking doses in targets and critical structures during CT-guided radiotherapy...
  66. ncbi Polymeric retinoid prodrug PG-4HPR enhances the radiation response of lung cancer
    Guangying Zhu
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncol Rep 18:645-51. 2007
    ..These results suggest that a polymeric delivery system may be useful for modulating radiosensitivity...
  67. ncbi Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma
    Xian Shu Gao
    Department of Radiation Oncology, Beijing University First Hospital, Beijing, P R China
    Int J Radiat Oncol Biol Phys 67:389-96. 2007
    ..To clarify the radiotherapy clinical target volume (CTV) margin needed for esophageal squamous-cell carcinoma (SCC) and gastroesophageal junction (GEJ) adenocarcinoma...
  68. ncbi Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex
    David J Yang
    Division of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Anticancer Drugs 15:255-63. 2004
    ..5 to 4 h in tumor-bearing animal models. We conclude that Tc-EC-CBX may be useful to assess tumor COX-2 expression. This may be useful in the future for selecting patients for treatment with anti-COX-2 agents...
  69. ncbi Comparison of efficacy of regional and extensive clinical target volumes in postoperative radiotherapy for esophageal squamous cell carcinoma
    Xue Ying Qiao
    Department of Radiation Oncology, Hebei Medical University Fourth Hospital, Shijiazhuang, People s Republic of China
    Int J Radiat Oncol Biol Phys 70:396-402. 2008
    ..To compare and analyze the effect of different clinical target volumes (CTVs) on survival rate after postoperative radiotherapy (RT) for esophageal squamous cell carcinoma (SCC)...
  70. ncbi Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer
    Tingyi Xia
    Department of Radiation Oncology, Air Force General Hospital, Beijing, People s Republic of China
    Int J Radiat Oncol Biol Phys 66:117-25. 2006
    ..To evaluate the efficacy and toxicity of hypofractionated stereotactic body radiotherapy in patients with Stage I/II non-small-cell lung cancer...
  71. ncbi Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience
    Shulian Wang
    Department of Radiation Oncology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    J Thorac Oncol 1:252-9. 2006
    ..The authors' results suggest that a total radiation dose of 50 to 65 Gy with a concurrent chemotherapy regimen may improve local control and the OS rate in this rare type of esophageal cancer...
  72. ncbi Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy
    Zhen Zhang
    Department of Radiation Oncology, Shanghai Fudan University, Shanghai Medical University, Shanghai Cancer Hospital, Shanghai, People's Republic of China
    Int J Radiat Oncol Biol Phys 61:656-64. 2005
    ..A threshold of tumor response to radiation dose might be present, as suggested by the flattened slope in the high-dose area on the dose-response curve. A carefully designed dose-escalation study is required to confirm this assumption...
  73. ncbi Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery
    Jing Jin
    Department of Radiation Oncology, Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China
    Int J Radiat Oncol Biol Phys 60:427-36. 2004
    ..Our data suggest that a randomized trial comparing CHT+CHT/RT+S and CHT/RT+S is warranted to assess further the merits of this treatment in patients with this currently very lethal cancer...
  74. ncbi Telomerase: a potential molecular marker and therapeutic target for cancer
    Joe Y Chang
    J Surg Oncol 87:1-3. 2004
  75. ncbi Non-small cell lung cancer clinical practice guidelines in oncology
    David S Ettinger
    J Natl Compr Canc Netw 4:548-82. 2006